PARIS -- A first-in-class dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4) improved lung function and reduced symptom burden for patients with moderate-to-severe chronic obstructive pulmonary ...
Researchers have found that phosphodiesterase 3 (PDE3) inhibitors have the ability to boost long bone growth. Conventionally used to treat heart disease, thrombosis, and asthma, PDE3 inhibitors can ...
Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "RPL554 Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers ...
Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone. This process requires the synthesis of extracellular matrix ...
Phosphodiesterase 3 (PDE3) inhibitors are clinically approved drugs used for treating thrombosis, heart diseases, and asthma. Now, however, scientists have found that PDE3 inhibitors can also ...
GSK and Hengrui Pharma collaborate on treatments for respiratory, immunology, inflammation, and oncology, including a PDE3/4 inhibitor for COPD. GSK gains an exclusive license for Hengrui's COPD ...
Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido [6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the ...
Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease ...
A new study identifies PDE3A mutations as the cause of brachydactyly type E with hypertension. These mutations alter PDE3A activity by uncovering cryptic sites for phosphorylation by PKA and PKC, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results